Damora Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
221 CRESCENT STREET, WALTHAM, MA, 02453
Mailing Address
221 CRESCENT STREET, WALTHAM, MA, 02453
Phone
(781) 281-9020
Fiscal Year End
1231
EIN
371957007
Financial Overview
FY2025
$240.38M
Stockholders' Equity
$3.98
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | April 1, 2026 | View on SEC |
| 3 Initial insider ownership report | April 1, 2026 | View on SEC |
| 4 Insider stock transaction report | March 25, 2026 | View on SEC |
| 4 Insider stock transaction report | March 25, 2026 | View on SEC |
| 3 Initial insider ownership report | March 25, 2026 | View on SEC |
| 4 Insider stock transaction report | March 25, 2026 | View on SEC |
| 3 Initial insider ownership report | March 25, 2026 | View on SEC |
| 4 Insider stock transaction report | March 25, 2026 | View on SEC |
| 4 Insider stock transaction report | March 25, 2026 | View on SEC |
| 4 Insider stock transaction report | March 25, 2026 | View on SEC |
Annual Reports
10-K
March 19, 2026
- Biotechnology company focused on developing new medicines, currently in the preclinical stage.
- Successfully completed a major acquisition in November 2025, integrating early drug development assets.
Material Events
8-K
Leadership Change
March 23, 2026
High Impact
- Damora Therapeutics appointed Jennifer Jarrett as President and CEO, bringing vast experience in biopharma operations, finance, corporate development, and investment banking.
- The Board of Directors was strengthened with two new, experienced members (Michael Landsittel and Cameron Turtle) who have proven track records in financial management, commercialization, and company building.
Insider Trading
SELL
3 insiders
3 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.